MedPath

GE HealthCare's Aurora SPECT/CT and Clarify DL Receive FDA Clearance, Advancing Nuclear Medicine Imaging

• GE HealthCare has received FDA 510(k) clearance for its Aurora nuclear medicine system and Clarify DL, with University Hospitals in Cleveland becoming the first U.S. institution to adopt this technology.

• The advanced dual-head SPECT/CT system features a 40mm detector with twice the coverage of other hybrid systems, 128-slice capability, and AI-powered deep learning reconstruction to enhance image quality without increasing radiation dose.

• Clinical evaluations demonstrated Clarify DL's superior image resolution in 98% of exams, supporting applications across cardiology, oncology, and neurology while accommodating patients with high BMI through workflow innovations.

GE HealthCare announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Aurora nuclear medicine system and Clarify DL, an advanced dual-head SPECT/CT designed to enhance diagnostic capabilities and streamline clinical workflows. University Hospitals in Cleveland, Ohio has become the first healthcare system in the United States to install this technology.
The Aurora system represents a significant advancement in nuclear medicine imaging, offering improved image quality and operational efficiency to support precision medicine initiatives. The system's integration of SPECT and CT components allows clinicians to perform comprehensive diagnostic exams in a single session, while its Clarify DL deep-learning image reconstruction technology enhances image quality without increasing radiation dose or scan time.
"We are thrilled to be the first in the United States to adopt this incredibly impressive technology," said Dr. Donna Plecha, Chair Department of Radiology, Radiologist-in-Chief, and Ida and Irwin Haber and Wei-Shen Chin, MD Chair in Radiology, at University Hospitals. "Aurora's seamless integration of SPECT and CT components will allow us to perform comprehensive, high-quality diagnostic exams in a single session, while its support of Clarify DL deep-learning image reconstruction enables enhanced image quality performance."

Technical Advancements in Nuclear Medicine Imaging

The Aurora system features a 40 mm detector, providing twice the detector coverage compared to CTs of other hybrid systems, along with 128-slice capability and intelligent imaging features. These specifications support a wide range of clinical applications across cardiology, oncology, and neurology.
The system's 5/8-inch crystal NaI detectors make it suitable for various clinical radiopharmaceuticals, including those used in the rapidly evolving field of theranostics, which combines diagnostic and therapeutic applications in nuclear medicine.
Clarify DL, the AI-powered image reconstruction solution, leverages deep learning technology to enhance bone SPECT image quality. In clinical evaluations, Clarify DL's image resolution was rated as superior in 98% of exams, demonstrating its potential to transform nuclear medicine bone SPECT imaging diagnostics. Unlike traditional noise reduction techniques that may compromise contrast and resolution, Clarify DL optimizes reconstruction while maintaining image quality.

Workflow Improvements and Patient Experience

Beyond imaging capabilities, Aurora incorporates "Effortless Workflow" solutions designed to streamline technologists' work from pre-scan to post-scan. These automation and design innovations aim to enhance patient comfort, including accommodations for patients with high BMI.
"Patient flow and overall operational efficiency are crucial for us, making Aurora the ideal choice to help meet our needs," said Percival Kane, Chief Operating Officer, University Hospitals Ahuja Medical Center. "Additionally, we're excited that Aurora's Revolution Ascend CT technology matches what is used in our radiology department daily."

Meeting the Demands of Precision Medicine

As healthcare continues to shift toward precision medicine and personalized care, advanced SPECT/CT solutions that provide greater diagnostic accuracy and efficiency are increasingly important. The ability to monitor and tailor treatments to individual patients depends on high-quality imaging that can detect subtle disease markers with confidence.
Jean-Luc Procaccini, President and CEO of Molecular Imaging and Computed Tomography at GE HealthCare, emphasized the significance of these advancements: "Aurora and Clarify DL are powerful reflections of GE HealthCare's ongoing investment in next-generation imaging solutions that empower clinicians to practice precision medicine and make more informed decisions. By providing diagnostic precision while enabling improved workflow, these nuclear medicine technologies allow clinicians to deliver effective, patient-centered care—ultimately helping drive better outcomes."

Strategic Collaboration for Clinical Excellence

University Hospitals' purchase of GE HealthCare's Aurora SPECT/CT with Clarify DL, Effortless Workflow, and MIM Software solutions reflects a strategic collaboration between the two institutions. This partnership aims to provide contemporary equipment and digital solutions to improve processes for the benefit of patients and clinicians alike, with a focus on implementing enterprise-wide technology to optimize workflows and improve clinical decision-making.
The FDA clearance of Aurora and Clarify DL marks a significant milestone in nuclear medicine imaging, offering healthcare providers advanced tools to enhance diagnostic capabilities, streamline workflows, and ultimately improve patient care in the era of precision medicine.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

© Copyright 2025. All Rights Reserved by MedPath